Picture EBD Group ChinaBio Partnerting Forum 2021 651x80
Document › Details

Keranova S.A.. (4/11/16). "Press Release: Keranova Raises €4m ($4.55m) in Series A Funding. Investment Will Finance Development of Prototypes for New Ophthalmic Surgery Equipment". Saint-Etienne & Lyon.

Organisations Organisation Keranova S.A.
  Organisation 2 Bpifrance
  Group France (govt)
Products Product surgical instrument
  Product 2 venture capital
Index term Index term Keranova–SEVERAL: investment, 201604 financing round Series A €4m led by Mérieux Développement + CEA Investissement plus Bpifrance
Persons Person Romano, Fabrice (Keranova 2015– CEO + Founder before EyeTechCare Founder + CEO)
  Person 2 Calenda, Valérie (Mérieux 201604 Partner at Mérieux Développement)

Keranova, a company that develops instruments for ophthalmic surgery, today announces series A funding of €4m ($4.55m). The round was led by Mérieux Développement in tandem with CEA Investissement. Additional support for the funding round came from French public investment bank Bpifrance, which contributed EUR 1 million (USD 1.14 million). The funds raised will finance the development of prototype surgical equipment and the preclinical study; a regulatory prerequisite for filing for approval of the clinical trial.

Keranova has developed a new and unique surgical instrument that leverages the results of joint research by two world-renowned multidisciplinary teams at Saint-Etienne’s Jean Monnet University.

This technological innovation developed by Keranova offers a new approach to surgical procedures and allows for a substantial reduction in manual intervention in favor of automation and precision. This will generate reproducibility and reduction of clinical risk (operator-dependent risk).
Keranova has its headquarters in the city of Saint-Etienne, where an exceptional concentration of academic laboratories engaged in excellent research has made it possible to found the company and ensure a plentiful supply of skills and high-quality human resources. Keranova also enjoys the support of the Saint-Etienne metropolitan authority.

“We aim to introduce a breakthrough innovation in the ophthalmology market, an area that is very open to technology, allowing us to overcome certain technological obstacles that were thought to be insurmountable,” said Fabrice Romano, founder and CEO of Keranova. “We are very pleased to welcome our new shareholders, two renowned investors who will help us make rapid inroads into the development of our first-generation product and the preparation of the clinical proof of concept.”

"Keranova’s technological advances should improve the accuracy and efficiency of surgery for several ophthalmologic diseases”, said Valérie Calenda, partner at Mérieux Développement. “We are delighted to fund this high potential industrial project in the Rhône-Alpes region and to support a team that has experience in the development and commercialization of innovative products.”
Keranova, founded in 2015, is the brainchild of Dr Fabrice Romano, former founding chairman & CEO of EyeTechCare, joined recently by Sophie Valla, managing director and former EMEA business development manager pharmaceutical/surgical with Bausch and Lomb / Valeant

Legal advisors to Keranova: François Pujol, Duteil avocats, Lyon, France.

Record changed: 2019-09-10


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Keranova S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top